CJC-1295 vs Ipamorelin
CJC-1295 and ipamorelin are growth-hormone secretagogues studied in somatotropic-axis research. They are classic complements: one is a GHRH analog, the other a selective ghrelin-receptor agonist, and the literature commonly investigates them as a pair.
| Aspect | CJC-1295 DAC | Ipamorelin |
|---|---|---|
| Secretagogue class | GHRH analog | Selective GHRP / ghrelin-receptor agonist |
| Signaling pathway studied | GHRH receptor | GHS-R1a (ghrelin) receptor |
| Selectivity note in literature | Extends GHRH signaling window | Studied for minimal effect on cortisol/prolactin pathways |
| Often researched with | Ipamorelin (complementary pathway) | CJC-1295 (complementary pathway) |
| Format / purity | Lyophilized · ≥99% HPLC | Lyophilized · ≥99% HPLC |
Two pathways, one axis
CJC-1295 acts at the GHRH receptor while ipamorelin acts at the ghrelin (GHS-R1a) receptor. Because these are distinct, complementary inputs to the somatotropic axis, the research literature frequently studies them together — which is why a combined preparation pairing CJC-1295 without DAC (Mod-GRF 1-29) with ipamorelin is also offered. Note that the standalone listed here is the long-acting DAC form, whereas the combination uses the shorter-acting no-DAC variant.
Why ipamorelin is described as selective
Ipamorelin is often characterized in the literature as a selective secretagogue studied for limited cross-activity with cortisol and prolactin pathways, distinguishing it from earlier GHRPs.
Questions
For Research Use Only. Not for human or animal consumption. The above is a neutral summary of compound class and published research context; it is not medical, dosing, or usage guidance, and has not been evaluated by the Food and Drug Administration.